Member Info for VertizeaSun

As clear as mud.

Bump

A claim that BEGO has SI status for trading #avct

It appears that BEGO is buying for a client on a "frequent and substantial basis"

https://twitter.com/boy_cellar/status/1579099006202183683

And also this :

"In vitro cytotoxicity assessments involving human tumor cell lines showed that AVA6000 was between 80-fold to 4,000-fold less cytotoxic compared to doxorubicin. In several in vivo efficacy studies in tumours with high FAP levels, AVA6000 significantly decreased tumor volume and increased survival in a dose-dependent manner."

Avacta will soon participate in three public events and too right if you've got news the world wants to hear:

1: David Wilson speaking at a Corona Virus conference on 19th October

2: Avacta will be attending Bio-Europe at Leipzig - a deal makers conference on 24-26 October.

3: Diagnostics will be attending Medica 2022 in the States (LFT) on 14-27 November.

And we've been promised our own science day in November. Roll-up folks.

Avacta needs a serious sale of something ( license, LFT's, whatever) to drive it quickly over £3 to clear those angry PI's that bought into the Covid ramp.

Their losses are a dead weight......especially on low volume AIM.

Silly Energyshares -to cover up his tracks and confound the investigators. Every conspiracy theorist knows that!

Only one?

meta property="article:modified_time" content="2022-04-05T13:08:59+00:00"

And this contradicts my own posting. I think digitalman is probably correct.
From the page head....5 April 22:

DATE ON LAST LINE
HTTP Headers
HTTP/1.1 301 Moved Permanently
Server: nginx
Date: Mon, 03 Oct 2022 08:49:24 GMT
Content-Type: text/html
Content-Length: 162
Connection: keep-alive
Location: https://avacta.com/therapeutics/precision/
HTTP/2 200
server: nginx
date: Mon, 03 Oct 2022 08:49:24 GMT
content-type: text/html; charset=UTF-8
content-length: 53584
vary: Accept-Encoding
last-modified: Fri, 30 Sep 2022 14:40:02 GMT

Further to Bella's post:

Rob Porter is founder of RAPivD and their web site lists Avacta as a collaborator/customer for Lateral Flow Testing. This man is working on a very different level compared to Abingdon or Medusa:

Rob Porter

CEO and founder of RAPivD, a scientific R&D company focused on diagnostics platforms such as lateral flow, electrochemical and op to electrical systems. He began his career with Unilever before transferring to the UK’s NationalPhysics Laboratory, building a bio sensing patent portfolio before spinning out Argento Diagnostics.Subsequently, Rob has held seniorBoard positions (CEO, CTO, COO) with a slate of UK diagnostic companies and has recently served as an adviser to the UK Health Service in respect of scale-up manufacturing for COVID rapid testing.

Thanks gadgie - surely Avacta will release product details prior to public display.

AVCT
Can put this one to bed for you Scott. 6mins30secs in Fiona says “where we can we are also taking tumour biopsies”
That’s was from the horses mouth 7 months ago.
They aren’t waiting til C4

youtube.com
Q&A with Avacta's CEO Alastair Smith & CSO Fiona McLaughlin
Assuming the clinical data for AVA6000 continues to be positive – then there should be several major ‘value inflexion points’ for Avacta over the next few ye...

When?

The next dose is due about the 13th October. Anything could happen from the week following that. Professor Udai Banerji will likely know everything he needs to know in respect of AVA6000 impact.

We got the news today.

Any decent CFO will keep a US$ bank account and run receivables and expenditure through it. So no disadvantage.

xNoz - exactly right. Spot on.

Two bots talking to each other. Clever technology.